Monoclonal antibodies to lipoarabinomannan/arabinomannan - characteristics and implications for tuberculosis research and diagnostics

Trends Microbiol. 2023 Jan;31(1):22-35. doi: 10.1016/j.tim.2022.07.001. Epub 2022 Jul 30.

Abstract

Antibodies to the mycobacterial surface lipoglycan lipoarabinomannan (LAM) and its related capsular polysaccharide arabinomannan (AM) are increasingly important for investigations focused on both understanding mechanisms of protection against Mycobacterium tuberculosis (Mtb) and developing next-generation point-of-care tuberculosis (TB) diagnostics. We provide here an overview of the growing pipeline of monoclonal antibodies (mAbs) to LAM/AM. Old and new methodologies for their generation are reviewed and we outline and discuss their glycan epitope specificity and other features with implications for the TB field.

Keywords: antigen–antibody interactions; biomarker; glycans; lipoglycans; mycobacteria; oligosaccharides; point-of-care tests.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Humans
  • Lipopolysaccharides
  • Mycobacterium tuberculosis*
  • Tuberculosis* / microbiology

Substances

  • lipoarabinomannan
  • Lipopolysaccharides
  • arabinomannan
  • Antibodies, Monoclonal